Publications dans lesquelles il/elle collabore avec José Ramón Blanco Ramos (17)

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection

    Trials, Vol. 22, Núm. 1

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Reproductive history before and after HIV diagnosis: A cross-sectional study in HIV-positive women in Spain

    Medicine (United States), Vol. 96, Núm. 5

2015

  1. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

  2. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

    HIV Clinical Trials, Vol. 16, Núm. 1, pp. 43-48

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

2014

  1. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 9

  2. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  3. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2013

  1. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: The TRIP study

    HIV Clinical Trials, Vol. 14, Núm. 5, pp. 204-215

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART

    Current HIV Research, Vol. 7, Núm. 6, pp. 612-619

2008

  1. Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status

    International Journal of Tuberculosis and Lung Disease, Vol. 12, Núm. 12, pp. 1393-1400

  2. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy

    Current HIV Research, Vol. 6, Núm. 2, pp. 100-107